{
    "clinical_study": {
        "@rank": "58711", 
        "arm_group": {
            "arm_group_label": "Brentuximab vedotin", 
            "arm_group_type": "Experimental", 
            "description": "1.8 mg/kg IV infusion"
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the\n      efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or\n      refractory Systemic Anaplastic Large Cell Lymphoma (SALCL)."
        }, 
        "brief_title": "Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Anaplastic Large-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Large-Cell, Anaplastic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients age 18 years or older, with relapsed or refractory sALCL who\n             have previously received at least 1 multiagent chemotherapy\n\n          -  Bidimensional measurable disease\n\n          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Female patients who are postmenopausal for at least 1 year before the screening\n             visit, surgically sterile, or agree to practice 2 effective methods of contraception,\n             at the same time, from the time of signing the informed consent form through 30 days\n             after the last dose of study drug, or agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception during the entire\n             study treatment period through 6 months after the last dose of study drug or agree to\n             practice true abstinence\n\n          -  Clinical laboratory values as specified in the study protocol\n\n        Exclusion Criteria:\n\n          -  Previous treatment with brentuximab vedotin.\n\n          -  Previously received an allogeneic transplant.\n\n          -  Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has\n             transformed to sALCL are eligible).\n\n          -  Known cerebral/meningeal disease including signs or symptoms of progressive\n             multifocal leukoencephalopathy (PML)\n\n          -  Female patients who are lactating and breastfeeding or pregnant\n\n          -  Known human immunodeficiency virus (HIV) positive\n\n          -  Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C\n             infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909934", 
            "org_study_id": "C25006", 
            "secondary_id": [
                "2012-004128-39", 
                "U1111-1154-9784"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Brentuximab vedotin", 
            "description": "Brentuximab vedotin will be administered as a single intravenous (IV) infusion over 30 minutes on Day 1 of each 3 week cycle for up to a maximum of 16 cycles and should be administered for a minimum of 8 cycles for patients who achieve stable disease or better.", 
            "intervention_name": "brentuximab vedotin", 
            "intervention_type": "Drug", 
            "other_name": [
                "SGN-35", 
                "ADCETRIS"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lymphoma", 
            "Anaplastic Large-cell", 
            "Relapsed", 
            "Refractory", 
            "Antigens, CD30", 
            "Antibody-Drug Conjugate", 
            "Antibodies, Monoclonal", 
            "Lymphoma, Non-Hodgkin", 
            "Lymphoma, Large-Cell, Anaplastic", 
            "monomethyl auristatin E", 
            "Drug Therapy", 
            "Immunotherapy", 
            "Hematologic Diseases"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "0032 321 77206"
                }, 
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium"
                    }, 
                    "name": "ZNA Stuivenberg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "32 2 764 1800"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Cliniques Universitaires Saint-Luc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "32 9 332 21 32"
                }, 
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+32 16 346900"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "University Hospital Leuven (UZ Leuven)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+420 53 223 3642"
                }, 
                "facility": {
                    "address": {
                        "city": "Jihlavska 20", 
                        "country": "Czech Republic", 
                        "state": "Brno"
                    }, 
                    "name": "University Hospital Brno"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+420 267 162 292"
                }, 
                "facility": {
                    "address": {
                        "city": "Srobarova 50", 
                        "country": "Czech Republic", 
                        "state": "Praha 10"
                    }, 
                    "name": "Fakultni nemocnice Kralovske Vinohrady"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "420 588 440 330"
                }, 
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Dept. of Hemato-Oncology, University Hospital in Olomouc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "420 224 962 0161"
                }, 
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Klinika hematologie VFN a 1.LFUK Vseobecna fakultni nemocnice v Praze"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+48 (0) 58 349 2233"
                }, 
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland"
                    }, 
                    "name": "Akademickie Centrum Kliniczne Szpital AMG"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "0048 12 295 41 39"
                }, 
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "Malopolskie Centrum Kliniczne S.C"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "0048 22 546 22 33"
                }, 
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }, 
                    "name": "Klinika Nowotworow Ukladu Chlonnego"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "0034-932-706100"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Vall d Hebron"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "0044 1872 252 506"
                }, 
                "facility": {
                    "address": {
                        "city": "Truro", 
                        "country": "United Kingdom", 
                        "state": "Cornwall"
                    }, 
                    "name": "Royal Cornwall Hospital NHS Trust"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "0044 161 446 3753"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "The Christie NHS Foundation Trust"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Czech Republic", 
                "Poland", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the antitumor efficacy of single-agent brentuximab vedotin as measured by ORR in patients with relapsed or refractory sALCL following at least 1 multiagent chemotherapy regimen", 
            "measure": "Objective Response Rate (ORR) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma", 
            "safety_issue": "No", 
            "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the duration of response with brentuximab vedotin.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
            }, 
            {
                "description": "To determine progression-free survival with brentuximab vedotin.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
            }, 
            {
                "description": "To determine the complete remission rate with brentuximab vedotin.", 
                "measure": "Complete remission rate (CR)", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, death or study closure (up to 5 years after the enrollment of the last patient)"
            }, 
            {
                "description": "To determine overall survival with brentuximab vedotin.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Until death or study closure (up to 5 years after the enrollment of the last patient)"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}